Endocrine Abstracts

Introduction: Many type 2 diabetes patients continue to have poor glycaemic control and would benefit from insulin therapy. One of the risks that hinders insulin use is hypoglycemia. Optimal insulin therapy should therefore minimize the risk of hypoglycemia while improving glycemic control. Newer insulin preparations degludec and glargin 300 units/ml show more even and prolonged pharmacokinetic profile, enabling an evenly distributed daytime glucose-lowering effect with high r...